Conference Coverage

How to choose between highly effective HBV therapies


 

EXPERT ANALYSIS FROM GUILD 2018

However, in a patient who has preexisting bone or renal disease – or who is at increased risk for such disease based upon age greater than 60 years, a history of fragility fractures, chronic systemic corticosteroid therapy, or renal abnormalities – entecavir or TAF is a better option than TDF.

TAF becomes the preferred choice over entecavir if the patient has previously been exposed to a nucleoside or if the patient is coinfected with HIV because the drug is approved for treatment of HIV and HBV, while entecavir is not.

Also, no dose adjustment of TAF is needed so long as the creatinine clearance is at least 15 mL/min, whereas the dose-adjustment threshold is 50 mL/min for both entecavir and TDF.

Pages

Recommended Reading

New trial to assess HIV+/HIV+ kidney transplants
MDedge Internal Medicine
Cochrane report: HPV vaccine proves its worth in adolescent, young adult women
MDedge Internal Medicine
Emotional regulation training lowers risk of adolescents having sex
MDedge Internal Medicine
Zika topped Lyme in 2016
MDedge Internal Medicine
Analysis finds inconsistent uptake of meningococcal B vaccines
MDedge Internal Medicine
MDedge Daily News: Do HPV vaccines really cut cancer risk?
MDedge Internal Medicine
ESBL-resistant bacteria spread in hospital despite strict contact precautions
MDedge Internal Medicine
Simple QI intervention helped improve HPV vaccination rates
MDedge Internal Medicine
ESBL-B before colorectal surgery ups risk of surgical site infection
MDedge Internal Medicine
FDA: PrEP indication updated to include adolescents at risk of HIV infection
MDedge Internal Medicine